Intelligence · Clinical Development
Pipeline search results
Programs matching “eli lilly” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 169 pipeline programs matching "eli lilly" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Orforglipron
Eli Lilly and Company
Peripheral Arterial Disease
1 trial -
Orforglipron
Eli Lilly and Company
OSA
1 trial -
Orforglipron, Placebo to match LY3502970
Eli Lilly Co.
Obesity, Overweight
1 trial -
Pemetrexed
Eli Lilly and Company
Non-Small Cell Lung Cancer
2 trials -
Placebo
Eli Lilly and Company
Hepatocellular Carcinoma
1 trial -
Placebo to match LY
Eli Lilly Co.
Overweight or Obesity, OSA (Obstructive Sleep Apnea)
1 trial -
Placebo to match LY, Muvalaplin
Eli Lilly Co.
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
1 trial -
RAMUCIRUMAB, ERLOTINIB
Eli Lilly Co.
Metastatic Non-Small Cell Lung Cancer
1 trial -
Ramucirumab
Eli Lilly and Company
Urothelial Carcinoma
1 trial -
Remternetug, Placebo to match LY
Eli Lilly Co.
Alzheimer’s Disease
1 trial -
Selpercatinib
Eli Lilly and Company
Non-Small Cell Lung Cancer
1 trial -
Tadalafil
Eli Lilly and Company
Hypertension, Pulmonary
1 trial -
Tasisulam-sodium
Eli Lilly and Company
Melanoma
1 trial -
Teriparatide
Eli Lilly and Company
Femur Neck Fracture
1 trial -
Testosterone MD-Lotion
Eli Lilly and Company
Hypogonadism
1 trial -
Tirzepatide
Eli Lilly and Company
Metabolic Dysfunction-Associated Steatotic Liver Disease
1 trial -
enzastaurin
Eli Lilly and Company
Glioblastoma
1 trial -
pemetrexed
Eli Lilly and Company
Head and Neck Neoplasms
1 trial -
ramucirumab
Eli Lilly and Company
Gastric Cancer
1 trial -
0.9% sodium chloride, GADOTERIC ACID
Eli Lilly Co.
Relapsing Multiple Sclerosis
1 trial -
Donanemab
Eli Lilly and Company
Cognitive Dysfunction
1 trial -
Eltrekibart
Eli Lilly and Company
Ulcerative Colitis
1 trial -
Eltrekibart, 0.9% sodium chloride
Eli Lilly Co.
Moderate to Severe Hidradenitis Suppurativa
1 trial -
Flortaucipir, Placebo to match LY3372689
Eli Lilly Co.
Alzheimer Disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.